行情

AKBA

AKBA

Akebia
NASDAQ

实时行情|Nasdaq Last Sale

4.280
+0.135
+3.26%
交易中 15:49 10/15 EDT
开盘
4.160
昨收
4.145
最高
4.400
最低
4.150
成交量
33.49万
成交额
--
52周最高
10.45
52周最低
3.500
市值
5.09亿
市盈率(TTM)
-1.7606
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AKBA 新闻

  • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Business Wire.10/02 20:05
  • Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque?
  • Simply Wall St..10/02 17:27
  • Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
  • Business Wire.09/24 12:00
  • fitbit暴跌500%后暴涨12% 谷歌会接盘以此对抗苹果吗
  • 钛媒体.09/21 14:56

更多

所属板块

生物技术和医学研究
+1.94%
制药与医学研究
+1.28%

热门股票

名称
价格
涨跌幅

AKBA 简况

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
展开

Webull提供Akebia Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。